G. Becker, N. Streichenberger, T. Billard, A. Newman-tancredi, and L. Zimmer, Receptor-binding Sites in Alzheimer's Disease, CNS Neuroscience & Therapeutics, vol.132, issue.10, pp.930-934, 2014.
DOI : 10.1093/brain/awp069

G. Becker, J. Colomb, V. Sgambato-faure, L. Tremblay, T. Billard et al., Preclinical evaluation of [18F]2FNQ1P as the first fluorinated serotonin 5-HT6 radioligand for PET imaging, European Journal of Nuclear Medicine and Molecular Imaging, vol.98, issue.3, pp.495-502, 2015.
DOI : 10.1016/j.pbb.2010.12.021
URL : https://hal.archives-ouvertes.fr/hal-01128421

A. Chakrabarti, A. Bagnall, P. Chue, M. Fenton, V. Palaniswamy et al., Loxapine for schizophrenia, Cochrane Database of Systematic Reviews, vol.39, issue.2, p.1943, 2007.
DOI : 10.1002/14651858.CD001943

C. Correll, From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics, European Psychiatry, vol.25, pp.12-21, 2010.
DOI : 10.1016/S0924-9338(10)71701-6

W. Glazer, Does loxapine have " atypical " properties? Clinical evidence, J Clin Psychiatry, vol.60, pp.42-46, 1999.

W. Hassoun, L. Carvoisin, M. Ginovart, N. Zimmer, L. Bonnefoi et al., PET study of the [ 11 C]raclopride binding in the striatum of the awake cat: effects of anaesthetics and role of cerebral blood flow, European Journal of Nuclear Medicine and Molecular Imaging, vol.30, issue.1, pp.141-148, 2003.
DOI : 10.1007/s00259-002-0904-4

S. Haugbøl, L. Pinborg, H. Arfan, V. Frøkjaer, J. Madsen et al., Reproducibility of 5-HT2A receptor measurements and sample size estimations with [18F]altanserin PET using a bolus/infusion approach, European Journal of Nuclear Medicine and Molecular Imaging, vol.18, issue.6, pp.910-915, 2007.
DOI : 10.1038/jcbfm.1992.81

J. Horacek, V. Bubenikova-valesova, M. Kopecek, T. Palenicek, C. Dockery et al., Mechanism of Action of Atypical Antipsychotic Drugs and the Neurobiology of Schizophrenia, CNS Drugs, vol.181, issue.2, pp.389-409, 2006.
DOI : 10.1093/schbul/19.1.119

S. Kapur, R. Zipursky, R. G. Jones, C. Mckay, G. Houle et al., PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: implications for the therapeutics of schizophrenia, Am J Psychiatry, vol.154, pp.525-1529, 1997.

G. Keating, Loxapine Inhalation Powder: A Review of its Use in the Acute Treatment of Agitation in Patients with Bipolar Disorder or Schizophrenia, CNS Drugs, vol.65, issue.3, pp.479-489, 2013.
DOI : 10.1111/j.1742-1241.2010.02615.x

I. Kusumi, S. Boku, and Y. Takahashi, Psychopharmacology of atypical antipsychotic drugs: From the receptor binding profile to neuroprotection and neurogenesis, Psychiatry and Clinical Neurosciences, vol.723, issue.Suppl. 2, pp.243-258, 2015.
DOI : 10.1016/j.ejphar.2013.10.060
URL : http://onlinelibrary.wiley.com/doi/10.1111/pcn.12242/pdf

K. Madsen, L. Marner, M. Haahr, N. Gillings, and G. Knudsen, Mass dose effects and in vivo affinity in brain PET receptor studies ??? a study of cerebral 5-HT4 receptor binding with [11C]SB207145, Nuclear Medicine and Biology, vol.38, issue.8, pp.1085-1091, 2011.
DOI : 10.1016/j.nucmedbio.2011.04.006

H. Meltzer, S. Matsubara, and J. Lee, Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin 2 pKi values, J Pharmacol Exp Ther, vol.251, pp.238-246, 1989.

K. Phillips, K. Bales, J. Capitanio, A. Conley, P. Czoty et al., Why primate models matter, American Journal of Primatology, vol.150, issue.266, pp.801-827, 2014.
DOI : 10.1002/ajpa.22185
URL : http://europepmc.org/articles/pmc4145602?pdf=render

D. Popovic, P. Nuss, and E. Vieta, Revisiting loxapine: a systematic review, Annals of General Psychiatry, vol.18, issue.4, p.15, 2015.
DOI : 10.1176/ajp.141.11.1490-a
URL : https://hal.archives-ouvertes.fr/hal-01143991

M. Seeman, Pharmacologic features and effects of neuroleptics, Can Med Assoc J, vol.125, pp.821-826, 1981.

P. Seeman, Atypical Antipsychotics: Mechanism of Action, The Canadian Journal of Psychiatry, vol.49, issue.2, pp.27-38, 2002.
DOI : 10.1016/S0920-9964(00)00083-9

A. Singh, C. Barlas, S. Singh, P. Franks, and R. Mishra, A neurochemical basis for the antipsychotic activity of loxapine: Interactions with dopamine D1, D2, D4, and serotonin 5-HT2 receptor subtypes, European Psychiatry, vol.11, pp.29-35, 1996.
DOI : 10.1016/0924-9338(96)89395-3

S. Stahl, Describing an atypical antipsychotic: receptor binding and its role in pathophysiology, Primary Care Companion J Clin Psychiatry, vol.5, pp.9-13, 2003.

H. Uchida, H. Takeuchi, A. Graff-guerrero, T. Suzuki, K. Watanabe et al., Dopamine D2 Receptor Occupancy and Clinical Effects, Journal of Clinical Psychopharmacology, vol.31, issue.4, pp.497-502, 2011.
DOI : 10.1097/JCP.0b013e3182214aad

L. Zimmer and A. Luxen, PET radiotracers for molecular imaging in the brain: Past, present and future, NeuroImage, vol.61, issue.2, pp.363-370, 2012.
DOI : 10.1016/j.neuroimage.2011.12.037
URL : https://hal.archives-ouvertes.fr/hal-00821153

J. Zohar, S. Stahl, H. Moller, P. Blier, D. Kupfer et al., A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature, European Neuropsychopharmacology, vol.25, issue.12, pp.2318-2325, 2015.
DOI : 10.1016/j.euroneuro.2015.08.019